Author: Erica Moyes
Joining in to co-create a strategy for the future
As we co-create our next organisation strategy we’re partnering with the people who have the greatest stake in driving change, our community. We want to bring you with us on this journey, and let you know the different points where you can be a voice for change. Hear from Involvement Champion, Neil Munn, about what it’s been like to help set this up and what he wants to see us achieve.
Medulloblastoma drug effect only seen with molecular profiling
Modern molecular profiling of medulloblastomas recently highlighted a previously unrecognised treatment benefit in a major international clinical trial.
A genetic mutation causing DMG and a potential drug to treat it
Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and, in lab studies working with model cell types, successfully reverse its effects to slow cancer cell growth with a targeted drug.
New MRI scans help monitor slow-growing tumours and guide treatment
A new MRI technique that enables doctors to better visualise what the brain is doing could identify specific areas of a slow-growing brain tumour that may be becoming more aggressive. New findings by scientists at the Erasmus University in Rotterdam suggest that visualising the whole tumour may be critical to identifying key changes and where patients may need more active treatment.
Telomeres- a cancer cell’s fountain of youth
If we can find a way to interrupt a cancer cell’s ability to keep dividing, we may have a key to stopping tumours growing. Researchers, Dr Wong and Dr Voon ,tells us about the discovery they made into a tumour’s ability to continuously divide.
Molecular profiles show up clinical trial benefits
Research we funded has added value to a clinical trial that started in 2004. Updated scientific techniques showed that some children with a medulloblastoma can safely be spared harmful treatments.
ACT NOW study update
We hear from two clinical psychologists who are helping young people after their brain tumour treatments through our ACT NOW study.
Stem cells are teaching us about glioblastoma
New research shows that stem cells may be primed to activate. This early stage research could lead us to the reason glioblastomas recur so quickly.
Brain tumour AI helping others
Artificial intelligence (AI) may be the key to fast and consistent renal cell tumour diagnoses, all because of work we fund on brain tumours.